Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 3 mg - capsule, hard - excipient ingredients: pregelatinised starch; sodium stearylfumarate; mannitol; croscarmellose sodium; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 2 mg - capsule, hard - excipient ingredients: croscarmellose sodium; mannitol; sodium stearylfumarate; pregelatinised starch; titanium dioxide; indigo carmine; purified water; iron oxide yellow; erythrosine; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 1 mg - capsule, hard - excipient ingredients: pregelatinised starch; croscarmellose sodium; mannitol; sodium stearylfumarate; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; ethanol absolute; ammonia - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: pregelatinised starch; mannitol; sodium stearylfumarate; croscarmellose sodium; titanium dioxide; indigo carmine; purified water; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - esomeprazole sodium, quantity: 42.5 mg (equivalent: esomeprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; water for injections; disodium edetate - the short-term management of gastro-oesophageal reflux disease (gord) in patients with oesophagitis and/or severe symptoms of reflux as an alternative when oral therapy is inappropriate.,prevention of rebleeding in patients following therapeutic endoscopy for acute, bleeding gastric or duodenal ulcers.,short-term management in patients requiring continued non-steroidal anti-inflammatory drug (nsaid) therapy when oral therapy is inappropriate:,? healing of gastric ulcers associated with nsaid therapy,? prevention of gastric and duodenal ulcers associated with nsaid therapy, in patients at risk,note: esomeprazole iv should be replaced with oral therapy as soon as practicable.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; gelatin; maize starch; macrogol 4000; magnesium stearate; hypromellose; lactose monohydrate - oral contraception

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg (equivalent: prednisolone, qty 5 mg) - suppository, moulded - excipient ingredients: hard fat - indications as at 01 jan 1991 : predsol suppositories are indicated for the treatment of haemorrhagic and granular proctitis, post-radiation proctitis and rectal complication of crohn's disease.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - isoniazid, quantity: 100 mg - tablet, uncoated - excipient ingredients: propyl hydroxybenzoate; colloidal anhydrous silica; wheat starch; calcium stearate; sodium benzoate; dextrin; microcrystalline cellulose; sodium starch glycollate; gelatin; maize starch; lactose monohydrate - indications as at 21 oct 1999 : treatment of pulmonary and extrapulmonary tuberculosis in combination with other antitubercular agents.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

boundary bend wellness pty ltd - olea europaea -